Why partner with us?
We have discovered, developed and commerzialized MVA-BN®-based products. In so doing, we
leverage our world-class expertise and governmental and scientific
network in all aspects of expressing, engineering, formulating and
producing vaccines.
That is how we take vaccines all the way from laboratory to
market.
We are committed to engineering vaccines into safe and effective
therapies, as well as to develop new Poxvirus-based vaccines.
You benefit from our IP and production capabilities when we
collaborate.
What we can offer you:
- We have extensive know-how and strong intellectual property
(IP) position with MVA-BN® vaccine technology and other
poxvirus-based technologies
- Our MVA-BN® vaccine is thoroughly tested, versatile and
broadly applicable, currently tested in more than 2,800
persons
- We have a state of the art, commercial scale vaccine manufacturing
facility for MVA based and other Poxvirus based vaccines
- We have excellent relationship with the US Government and other
Governments around the globe
- We focus on unmet medical needs and life threatening
diseases
You will benefit from partnering with us. Through a research
collaboration you get access to our versatile MVA-BN® IP and
production capabilities.
Our partnering principles is ruled by fairness: Decency is what
counts.
We recognise that each partner opportunity is unique and we have a
dedicated organisation and process in place to reflect this. In any
case, we want to be able to look you in the eye - before, during
and after our collaboration.
